Skorney believes that the high placebo response in AbbVie’s trials might indicate poor trial ... Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to ...

Acquired by AbbVie in its $9 billion Cerevel Therapeutics buy ... And while much of the attention during earnings season ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

AbbVie’s deal flop and NFL high-profile draft busts have a lot in common.

Many patients with IBD report persisting symptoms, despite resolution of the inflammatory process. Although by definition, a ...

There’s a big ol’ leak in Abbvie’s drug development pipeline. On Monday, the pharma giant announced that two mid-stage trials ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

AbbVie shares plunged after the pharma company's schizophrenia treatment came up short in a clinical trial, helping boost ...

Bristol-Myers Squibb is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Shares were recently up 11% after AbbVie reported ...

But I think part of the reason we're seeing such a significant sell-off is that it does bring into question the potential ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...